Skip to main content

Coronavirus: What is the MHRA doing?

Guidance for industry on flexible approaches to regulation the Medicines and Healthcare Agency (MHRA) are taking during the COVID-19 outbreak. The MHRA are working closely with the Department of Health and Social Care (DHSC) and other healthcare partners and stakeholders to rapidly develop a package of ‘flexibilities’ to regulatory guidance, in order to support the medicines supply chain and wider healthcare response to the COVID-19 outbreak in the UK.

These regulatory flexibilities are:
  • temporary and will be kept under review, except where regulatory extensions have been stated
  • offered to provide flexibility in exceptional circumstances 
  • effective immediately

See the full guidance here
We are all navigating uncharted waters as business and society faces up to the impact of COVID-19.  We very much hope you and your loved ones remain in good health. 

 Please be assured that Fieldfisher is continuing to work with clients to navigate COVID-19 related issues and on business as usual needs.  Do get in touch with us if you would like to chat anything through.


Sign up to our email digest

Click to subscribe or manage your email preferences.